js207
mAbexperimentalBi-specific
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2023 (NCT06022250)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07309276 | Phase 2 | Dec 30, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT07045311 | Phase 2 | Sep 17, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06924606 | Phase 2 | Jul 15, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06969027 | Phase 2 | Jun 19, 2025 | Innovaderm, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06954467 | Phase 2 | May 29, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06885385 | Phase 2 | Apr 23, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06944470 | Phase 2 | Apr 20, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06868836 | Phase 2 | Mar 28, 2025 | Innovaderm, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06022250 | Phase 1 | Sep 15, 2023 | Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 9 | 9 | 2 | 2023 |
| Innovaderm | For profit | 2 | 0 | 1 | 2025 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1